Fintel reports that on April 8, 2025, William Blair initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a ...

In a report released today, Andy Hsieh from William Blair maintained a Buy rating on Skye Bioscience (SKYE – Research Report). The company’s ...

William Blair initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $21 fair value estimate. Kalaris is a clinical-stage ...

The original musical “Why Can’t They See?”, written by Pastor Bill Blair, will be presented at 7 p.m. on Maundy Thursday, ...

William Blair Large Cap Growth Fund earns an Average Process Pillar rating. The leading factor in the rating is the stability of the management team. Specifically, the fund has not seen a manager ...

Healthcare Analysts, along with argenx ( ARGX) SE CEO Tim Van Hauwermeiren and Dr. Chafic Karam discuss Vyvgart on an Analyst/Industry conference call to be held on April 8 at 1 pm. Published first on ...

In a report released today, Matt Larew from William Blair maintained a Buy rating on 908 Devices (MASS – Research Report). The company’s shares opened today at $4.43. Discover outperforming ...

In a report released today, Jon Andersen from William Blair maintained a Buy rating on Simply Good Foods (SMPL – Research Report). The ...